Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review
Abstract Introduction Significant advances in the treatment of transthyretin (ATTR) amyloidosis has led to an evolving understanding of the epidemiology of this condition. This systematic literature review (SLR) aims to synthesize current evidence on epidemiology and mortality outcomes in ATTR amylo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Online Access: | https://doi.org/10.1186/s13023-025-03547-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594386503860224 |
|---|---|
| author | Diego Delgado Firas Dabbous Nitin Shivappa Faizan Mazhar Eric Wittbrodt Divya Shridharmurthy Krister Järbrink |
| author_facet | Diego Delgado Firas Dabbous Nitin Shivappa Faizan Mazhar Eric Wittbrodt Divya Shridharmurthy Krister Järbrink |
| author_sort | Diego Delgado |
| collection | DOAJ |
| description | Abstract Introduction Significant advances in the treatment of transthyretin (ATTR) amyloidosis has led to an evolving understanding of the epidemiology of this condition. This systematic literature review (SLR) aims to synthesize current evidence on epidemiology and mortality outcomes in ATTR amyloidosis, addressing the need for a comprehensive understanding of its current global impact. Methods An SLR of the literature from January 2018 to April 2023 was conducted using the Medline and Embase databases. The review followed the PRISMA guidelines. Studies evaluating populations with genotypes and phenotypes of ATTR amyloidosis (variant and wild-type cardiomyopathy, polyneuropathy, and mixed) were included. Observational studies, systematic reviews, and meta-analyses were eligible, while reports, commentaries, clinical trials, and non-ATTR amyloidosis studies were excluded. Extracted data included prevalence, incidence, and mortality rates. Results Of the 1,458 studies identified, 113 met the inclusion criteria. Forty-nine studies reported on epidemiology, while 64 focused on mortality rates in cohorts of patients with ATTR amyloidosis from Europe (n = 16), North America (n = 26), Asia (n = 5), and Australia (n = 2). No studies were found that exclusively focused on ATTR amyloidosis in Africa or South America. ATTR prevalence ranged from 6.1/million in the US to 232/million in Portugal with very limited data on ATTR-PN. The 2-year mortality risk ranged from 10 to 30% among wild-type ATTR-CM and from 10 to 50% for variant type of ATTR-CM. Conclusions This SLR demonstrated heterogeneity in ATTR epidemiology and mortality rates across global regions. Further investigation is needed to address knowledge gaps of the epidemiology and burden of ATTR, which may improve early diagnosis and management. |
| format | Article |
| id | doaj-art-0fb0f09ac5bc463aab59149bc7a9cfbb |
| institution | Kabale University |
| issn | 1750-1172 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj-art-0fb0f09ac5bc463aab59149bc7a9cfbb2025-01-19T12:38:25ZengBMCOrphanet Journal of Rare Diseases1750-11722025-01-0120111210.1186/s13023-025-03547-0Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature reviewDiego Delgado0Firas Dabbous1Nitin Shivappa2Faizan Mazhar3Eric Wittbrodt4Divya Shridharmurthy5Krister Järbrink6Division of Cardiology and Transplant, UHNData Analytics - Real World EvidenceCardiovascular, Renal and Metabolism (CVRM) Evidence, BioPharmaceuticals MedicalReal-World EvidenceCardiovascular, Renal and Metabolism (CVRM) Evidence, BioPharmaceuticals MedicalData Analytics - Real World EvidenceCardiovascular, Renal and Metabolism (CVRM) Evidence, BioPharmaceuticals MedicalAbstract Introduction Significant advances in the treatment of transthyretin (ATTR) amyloidosis has led to an evolving understanding of the epidemiology of this condition. This systematic literature review (SLR) aims to synthesize current evidence on epidemiology and mortality outcomes in ATTR amyloidosis, addressing the need for a comprehensive understanding of its current global impact. Methods An SLR of the literature from January 2018 to April 2023 was conducted using the Medline and Embase databases. The review followed the PRISMA guidelines. Studies evaluating populations with genotypes and phenotypes of ATTR amyloidosis (variant and wild-type cardiomyopathy, polyneuropathy, and mixed) were included. Observational studies, systematic reviews, and meta-analyses were eligible, while reports, commentaries, clinical trials, and non-ATTR amyloidosis studies were excluded. Extracted data included prevalence, incidence, and mortality rates. Results Of the 1,458 studies identified, 113 met the inclusion criteria. Forty-nine studies reported on epidemiology, while 64 focused on mortality rates in cohorts of patients with ATTR amyloidosis from Europe (n = 16), North America (n = 26), Asia (n = 5), and Australia (n = 2). No studies were found that exclusively focused on ATTR amyloidosis in Africa or South America. ATTR prevalence ranged from 6.1/million in the US to 232/million in Portugal with very limited data on ATTR-PN. The 2-year mortality risk ranged from 10 to 30% among wild-type ATTR-CM and from 10 to 50% for variant type of ATTR-CM. Conclusions This SLR demonstrated heterogeneity in ATTR epidemiology and mortality rates across global regions. Further investigation is needed to address knowledge gaps of the epidemiology and burden of ATTR, which may improve early diagnosis and management.https://doi.org/10.1186/s13023-025-03547-0 |
| spellingShingle | Diego Delgado Firas Dabbous Nitin Shivappa Faizan Mazhar Eric Wittbrodt Divya Shridharmurthy Krister Järbrink Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review Orphanet Journal of Rare Diseases |
| title | Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review |
| title_full | Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review |
| title_fullStr | Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review |
| title_full_unstemmed | Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review |
| title_short | Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review |
| title_sort | epidemiology of transthyretin attr amyloidosis a systematic literature review |
| url | https://doi.org/10.1186/s13023-025-03547-0 |
| work_keys_str_mv | AT diegodelgado epidemiologyoftransthyretinattramyloidosisasystematicliteraturereview AT firasdabbous epidemiologyoftransthyretinattramyloidosisasystematicliteraturereview AT nitinshivappa epidemiologyoftransthyretinattramyloidosisasystematicliteraturereview AT faizanmazhar epidemiologyoftransthyretinattramyloidosisasystematicliteraturereview AT ericwittbrodt epidemiologyoftransthyretinattramyloidosisasystematicliteraturereview AT divyashridharmurthy epidemiologyoftransthyretinattramyloidosisasystematicliteraturereview AT kristerjarbrink epidemiologyoftransthyretinattramyloidosisasystematicliteraturereview |